Seronegative Myasthenia Gravis with Concomitant SARS-CoV-2 Infection in a Dog

Musteață, Mihai; Borcea, Denis-Gabriel; Despa, Andreea; Ștefănescu, Raluca; Ivănescu, Larisa; Hrițcu, Luminiţa Diana; Baisan, Radu Andrei; Lăcătuş, Radu; Solcan, G.

doi:10.3390/vetsci9070318

Cited by 1 publication

(1 citation statement)

References 38 publications

(59 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Myasthenia gravis (MG) is an immune-mediated disorder impairing neuromuscular transmission through the production of antibodies against the post-synaptic component of the neuromuscular junction in skeletal muscle (1,2). The resulting clinical presentation is skeletal muscle weakness and fatigability which can affect skeletal muscles focally or in a generalized fashion (1).…”

Section: Introductionmentioning

confidence: 99%

Case report: Immune remission from generalized myasthenia gravis in a dog with a thymoma and cholangiocellular carcinoma

Mignan

White²,

Stee³

et al. 2023

Front. Vet. Sci.

View full text Add to dashboard Cite

A 9-year-old male neutered Cockapoo was presented with an acute and progressive history of exercise induced weakness involving all limbs, and bilateral decreased ability to blink. Investigations revealed generalized myasthenia gravis alongside the presence of a thymoma and a cholangiocellular carcinoma. Symptomatic treatment through pyridostigmine bromide was used to control clinical signs, and complete surgical removal of the thymoma and cholangiocellular carcinoma was performed. Serum acetylcholine receptor antibody concentration was measured serially. Clinical remission defined as resolution of clinical signs alongside discontinuation of treatment was achieved by day 251 (8.2 months). Immune remission defined as normalization of serum acetylcholine receptor antibody concentration alongside resolution of clinical signs and discontinuation of treatment was achieved by day 566 (18.5 months). Neurological examination was normal, and the owners did not report any clinical deterioration during the final follow-up appointment on day 752 (24 months), hence outcome was considered excellent. This is the first report describing the temporal evolution of serum acetylcholine receptor antibody concentration in a dog with thymoma-associated myasthenia gravis which achieved immune remission following thymectomy. Treatment was successfully discontinued without any evidence of clinical deterioration thereafter despite serum acetylcholine receptor antibody concentration not normalizing for another 315 days (10 months).

show abstract

Section: Introductionmentioning

confidence: 99%